Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis

OBJECTIVES: To describe the efficacy and safety through 5 years of adalimumab treatment in patients with ankylosing spondylitis (AS), and to identify predictors of remission. METHODS: Patients with active AS were followed up to 5 years during a 24-week randomised, controlled period, followed by an o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sieper, Joachim, van der Heijde, Désirée, Dougados, Maxime, Brown, L Steve, Lavie, Frederic, Pangan, Aileen L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329233/
https://www.ncbi.nlm.nih.gov/pubmed/22128084
http://dx.doi.org/10.1136/annrheumdis-2011-200358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329233/
https://www.ncbi.nlm.nih.gov/pubmed/22128084
http://dx.doi.org/10.1136/annrheumdis-2011-200358

Ejemplares similares